Secondary IDH mutations, IDH isoform switching, and alternative mutations in cellular differentiation pathways (e.g., TET2 and RUNX1) are known mechanisms of acquired resistance to ivosidenib in AML [99,100,101]. This evidence concerns the gene IDH1 and acute myeloid leukemia.